A novel insulin analog with unique properties: LysB3,Glu B29 insulin induces prominent activation of insulin receptor substrate 2, but marginal phosphorylation of insulin receptor substrate 1

Diabetes

Volumn 52, Issue 9, 2003, Pages 2227-2238

  Rakatzi, Irini ^a   Ramrath, Stefanie ^a   Ledwig, Daniela ^a   Dransfeld, Olaf ^a   Bartels, Thomas ^b   Seipke, Gerhard ^b   Eckel, Jürgen ^a  

^a LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HMR 1153; INSULIN; INSULIN DERIVATIVE; INSULIN GLULISINE; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN SHC; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS; DRUG ACTIVITY; DRUG BINDING; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; ENZYME ACTIVATION; HEART MUSCLE CELL; HEXOSE TRANSPORT; INSULIN DEPENDENT DIABETES MELLITUS; MITOGENESIS; MYOBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING; RISK FACTOR;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADAPTOR PROTEINS, VESICULAR TRANSPORT; AGE FACTORS; ANIMALS; CELL DIVISION; CELLS, CULTURED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MAP KINASE SIGNALING SYSTEM; MITOGENS; MYOCYTES, CARDIAC; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEINS; RATS; TYROSINE;

EID: 0042822147     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.52.9.2227     Document Type: Article

References (47)

1. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
2. Heinemann L, Starke AA, Hohmann A, Berger M: Timing between the subcutaneous administration of insulin and consumption of a carbohydrate rich meal. Horm Metab Res Suppl 26:137-139, 1992
3. Bolli GB, Di Marchi RD, Park GD, Pramming S, Koivisto VA: Insulin analogs and their potential in the management of diabetes mellitus. Diabetologia 42:1151-1167, 1999
4. Brange J, Volund A: Insulin analogs with improved pharmacokinetic profiles. Adv Drug Deliv Rev 35:307-35, 1999
5. Vajo Z, Duckworth WC: Genetically engineered insulin analogs: diabetes in the new millenium. Pharmacol Rev 52:1-9, 2000
6. Mosekilde E, Jensen KS, Binder C, Pramming S, Thorsteinsson B: Modeling absorption kinetics of subcutaneous injected soluble insulin. J Pharmacokinet Biopharm 17:67-87, 1989
7. Hildebrandt P, Sejrsen P, Nielsen SL, Birch K, Sestoft L: Diffusion and polymerization determines the insulin absorption from subcutaneous tissue in diabetic patients. Scand J Clin Lab Invest 45:685-690, 1985
8. Brange J, Owens DR, Kang S, Volund A: Monomeric insulins and their experimental and clinical implications. Diabetes Care 13:923-954, 1990
9. Slieker LJ, Brooke GS, DiMarchi RD, Flora DB, Green LK, Hoffmann JA, Long HB, Fan L, Shields JE, Sundell KL, Surface PL, Chance RE: Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor. Diabetologia 40:S54-S61, 1997
10. Drejer K: The bioactivity of insulin analogs from in vitro receptor binding to in vivo glucose uptake. Diabetes Metab Rev 8:259-285, 1992
11. Hansen BF, Danielsen GM, Drejer K, Sorensen AR, Wiberg FC, Klein HH, Lundemose AG: Sustained signalling from the insulin receptor after stimulation with insulin analogs exhibiting increased nutogenic potency. Biochem J 315:271-279, 1996
12. Kurtzhals P, Schaffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C, Trub T: Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49:999-1005, 2000
13. Bahr M, Kolter T, Seipke G, Eckel J: Growth promoting and metabolic activity of the human insulin analog [GlyA21,ArgB31,ArgB32] insulin (HOE 901) in muscle cells. Eur J Pharmacol 320:259-265, 1997
14. Shymko RM, Dumont E, De Meyts P, Dumont JE: Timing-dependence of insulin-receptor mitogenic versus metabolic signalling: a plausible model based on coincidence of hormone and effector binding. Biochem J 339:675-683, 1999
15. Milazzo G, Sciacca L, Papa V, Goldfine ID, Vigneri R: ASPB10 insulin induction of increased mitogenic responses and phenotypic changes in human breast epithelial cells: evidence for enhanced interactions with the insulin-like growth factor-I receptor. Mol Carcinog 18:19-25, 1997
16. Dransfeld O, Uphues I, Sasson S, Schurmann A, Joost HG, Eckel J: Regulation of subcellular distribution of GLUT4 in cardiomyocytes: Rab4A reduces basal glucose transport and augments insulin responsiveness. Exp Clin Endocrinol Diabetes 108:26-36, 2000
17. Eckel J, Pandalis G, Reinauer H: Insulin action on the glucose transport system in isolated cardiocytes from adult rat. Biochem J 212:385-392, 1983
18. Eckel J, Reinauer H: Involvement of hormone processing in insulin-activated glucose transport by isolated cardiac myocytes. Biochem J 249:111-116, 1988
19. Till M, Ouwens DM, Kessler A, Eckel J: Molecular mechanisms of contraction-regulated cardiac glucose transport. Biochem J 346:841-847, 2000
20. Kolter T, Uphues I, Eckel J: Molecular analysis of insulin resistance in isolated ventricular cardiomyocytes of obese Zucker rats. Am J Physiol 273:E59-E67, 1997
21. Slieker LJ, Brooke GS, DiMarchi RD, Flora DB, Green LK, Hoffmann JA, Long HB, Fan L, Shields JE, Sundell KL, Surface PL, Chance RE: Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor. Diabetologia 40:S54-S61, 1997
22. Drejer K, Kruse V, Larsen UD, Hougaard P, Bjorn S, Gammeltoft S: Receptor binding and tyrosine kinase activation by insulin analogs with extreme affinities studied in human hepatoma HepG2 cells. Diabetes 40:1488-1495, 1991
23. Di Guglielmo GM, Drake PG, Baass PC, Authier F, Posner BI, Bergeron JJ: Insulin receptor internalization and signalling. Mol Cell Biochem 182:59-63, 1998
24. Chow JC, Condorelli G, Snuth RJ: Insulin-like growth factor-I receptor internalization regulates signaling via the Shc/mitogen-activated protein kinase pathway, but not the insulin receptor substrate-1 pathway. J Biol Chem 273:4672-4680, 1998
25. Alessi DR, Saito Y, Campbell DG, Cohen P, Sithanandam G, Rapp U, Ashworth A, Marshall CJ, Cowley S: Identification of the sites in MAP kinase kinase-1 phosphorylated by p74raf-1. EMBO J 13:1610-1619, 1994
26. Eckel J, Reinauer H: The insulin receptor of adult heart muscle cells. Basic Res Cardiol 80:61-64, 1985
27. Kessler A, Uphues I, Ouwens DM, Till M, Eckel J: Diversification of cardiac insulin signaling involves the p85 alpha/beta subunits of phosphatidylinositol 3-kinase. Am J Physiol 280:E65-E74, 2001
28. Hajduch E, Litherland GJ, Hundal HS: Protein kinase B (PKB/Akt). A key regulator of glucose transport? FEBS Lett 492:199-203, 2001
29. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA: Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378:785-789, 1995
30. Bornfeldt KE, Gidlof RA, Wasteson A, Lake M, Skottner A, Arnqvist HJ: Binding and biological effects of insulin, insulin analogs and insulin-like growth factors in rat aortic smooth muscle cells: comparison of maximal growth promoting activities. Diabetologia 34:307-313, 1991
31. Baltensperger K, Kozma LM, Cherniack AD, Klarlund JK, Chawla A, Banerjee U, Czech MP: Binding of the Ras activator son of sevenless to insulin receptor substrate-1 signaling complexes. Science 260:1950-1952, 1993
32. Ouwens DM, van der Zon GC, Pronk GJ, Bos JL, Moller W, Cheatham B, Kahn CR, Maassen JA: A mutant insulin receptor induces formation of a Shc-growth factor receptor bound protein 2 (Grb2) complex and p21ras-GTP without detectable interaction of insulin receptor substrate 1 (IRS1) with Grb2: evidence for IRS1-independent p21ras-GTP formation. J Biol Chem 269:33116-33122, 1994
33. Pelech SL, Sanghera JS: Mitogen-activated protein kinases: versatile transducers for cell signaling. Trends Biochem Sci 17:233-238, 1992
34. Tartare-Deckert S, Sawka-Verhelle D, Murdaca J, Van Obberghen E: Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system. J Biol Chem 270:23456-23460, 1995
35. Kim B, Cheng HL, Margolis B, Feldman EL: Insulin receptor substrate 2 and Shc play different roles in insulin-like growth factor I signaling. J Biol Chem 273:34543-34550, 1998
36. Bevan AP, Seabright PJ, Tikerpae J, Posner BI, Smith GD, Siddle K: The role of insulin dissociation from its endosomal receptor in insulin degradation. Mol Cell Endocrinol 164:145-157, 2000
37. Vieira AV, Lamaze C, Schmid SL: Control of EGF receptor signaling by clathrin-mediated endocytosis. Science 274:2086-2089, 1996
38. Pierce KL, Maudsley S, Daaka Y, Luttrell LM, Lefkowitz RJ: Role of endocytosis in the activation of the extracellular signal-regulated kinase cascade by sequestering and nonsequestering G protein-coupled receptors. Proc Natl Acad Sci U S A 97:1489-1494, 2000
39. Miele C, Caruso M, Calleja V, Auricchio R, Oriente F, Formisano P, Condorelli G, Cafieri A, Sawka-Verhelle D, Van Obberghen E, Beguinot F: Differential role of insulin receptor substrate (IRS)-1 and IRS-2 in L6 skeletal muscle cells expressing the Arg1152→Gln insulin receptor. J Biol Chem 274:3094-3102, 1999
40. Rother KI, Imai Y, Caruso M, Beguinot F, Formisano P, Accili D: Evidence that IRS-2 phosphorylation is required for insulin action in hepatocytes. J Biol Chem 273:17491-17497, 1998
41. Valverde AM, Lorenzo M, Pons S, White MF, Benito M: Insulin receptor substrate (IRS) proteins IRS-1 and IRS-2 differential signaling in the insulin/insulin-like growth factor-I pathways in fetal brown adipocytes. Mol Endocrinol 12:688-697, 1998
42. Sobke A, Hennige AM, Strack V, Metzinger E, Seipke G, Häring H-U, Kellerer M: New human insulin analogues: characteristics of insulin binding and signaling in comparison to Asp(B10) and regular insulin (Abstract). Diabetes und Stoffwechsel 10 (Suppl. 1):22, 2001
43. Farooq A, Plotnikova O, Zeng L, Zhou MM: Phosphotyrosine binding domains of Shc and insulin receptor substrate 1 recognize the NPXpY motif in a thermodynamically distinct manner. J Biol Chem 274:6114-6121, 1999
44. Kido Y, Burks DJ, Withers D, Bruning JC, Kahn CR, White MF, Accili D: Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2. J Clin Invest 105:199-205, 2000
45. Yamauchi T, Tobe K, Tamemoto H, Ueki K, Kaburagi Y, Yamamoto-Honda R, Takahashi Y, Yoshizawa F, Aizawa S, Akanuma Y, Sonenberg N, Yazaki Y, Kadowaki T: Insulin signalling and insulin actions in the muscles and livers of insulin-resistant, insulin receptor substrate 1-deficient mice. Mol Cell Biol 16:3074-3084, 1996
46. Sawka-Verhelle D, Baron V, Mothe I, Filloux C, White MF, Van Obberghen E: Tyr624 and Tyr628 in insulin receptor substrate-2 mediate its association with the insulin receptor. J Biol Chem 272:16414-16420, 1997
47. Chaika OV, Chaika N, Volle DJ, Hayashi H, Ebina Y, Wang LM, Pierce JH, Lewis RE: Mutation of tyrosine 960 within the insulin receptor juxtamembrane domain impairs glucose transport but does not inhibit ligand-mediated phosphorylation of insulin receptor substrate-2 in 3T3-L1 adipocytes. J Biol Chem 274:12075-12080, 1999